Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Alissa Groenendijk

Alissa Groenendijk

PhD student
Risk factors for, and optimal treatment of relapsed Wilms tumors.
Phone 088 97 25 633

Over the past decades, implementation of international treatment protocols, including those designed by the International Society of Pediatric Oncology (SIOP), has improved overall survival of patients with Wilms tumors (WT) to more than 90% for local disease. Still, 15% to 50% of WT patients with suffer from relapses. To improve relapsed WT management, shared international protocols stratify WT (relapse) patients into risk groups based on prognostic factors. Adequate treatment regimens are assigned in accordance with these risk groups. This project is focused on the evaluation of the current prognostic factors for tumor relapse, survival after relapse in the different risk groups, and the effect of the corresponding relapse treatment. In addition, we culture tumor organoids of (primary and) relapsed WT tissue. Drug screens are performed on these organoids to determine effective (patient specific) treatment options and unravel targets for therapy.

  • Molecular Characterization Reveals Subclasses of 1q Gain in Intermediate Risk Wilms Tumors

    • okt. 2022
    • Ianthe A.E.M., van Belzen, et al
    • Cancers
  • Prognostic Factors for Wilms Tumor Recurrence

    • jun. 2021
    • Alissa, Groenendijk, et al
    • Cancers
View all publications